Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management

Cyrus Jahansouz, Hongliang Xu, Scott Kizy, Avis J. Thomas, Ajeetha Josephrajan, Ann M Hertzel, Rocio Foncea, John E Connett, Charles J Billington, Michael Jensen, Judith Korner, David A Bernlohr, Sayeed Ikramuddin

Research output: Contribution to journalArticle

Abstract

Background: Serum concentrations of fatty acid binding protein 4, an adipose tissue fatty acid chaperone, have been correlated with insulin resistance and cardiovascular risk factors. The objective of this study were to assess relationships among Roux-en-Y gastric bypass, intensive lifestyle modification and medical management protocol, fatty acid binding protein 4, and metabolic parameters in obese patients with severe type 2 diabetes mellitus; and to evaluate the relative contribution of abdominal subcutaneous adipose and visceral adipose to the secretion of fatty acid binding protein 4. Methods: Participants were randomly assigned to intensive lifestyle modification and medical management protocol (n = 29) or to intensive lifestyle modification and medical management protocol augmented with Roux-en-Y gastric bypass (n = 34). Relationships among fatty acid binding protein 4 and demographic characteristics, metabolic parameters, and 12-month changes in these values were examined. Visceral and subcutaneous adipose tissue explants from obese nondiabetic patients (n = 5) were obtained and treated with forskolin to evaluate relative secretion of fatty acid binding protein 4 in the different adipose tissue depots. Results: The intensive lifestyle modification and medical management protocol and Roux-en-Y gastric bypass cohorts had similar fasting serum fatty acid binding protein 4 concentrations at baseline. At 1 year, mean serum fatty acid binding protein 4 decreased by 42% in Roux-en-Y gastric bypass participants (P =.002) but did not change significantly in the intensive lifestyle modification and medical management protocol cohort. Percentage of weight change was not a significant predictor of 12-month fatty acid binding protein 4 within treatment arm or in multivariate models adjusted for treatment arm. In adipose tissue explants, fatty acid binding protein 4 was secreted similarly between visceral and subcutaneous adipose tissue. Conclusion: After Roux-en-Y gastric bypass, fatty acid binding protein 4 is reduced 12 months after surgery but not after intensive lifestyle modification and medical management protocol in patients with type 2 diabetes mellitus. Fatty acid binding protein 4 was secreted similarly between subcutaneous and visceral adipose tissue explants.

Original languageEnglish (US)
Pages (from-to)571-578
Number of pages8
JournalSurgery (United States)
Volume165
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Fatty Acid-Binding Proteins
Gastric Bypass
Serum
Life Style
Intra-Abdominal Fat
Subcutaneous Fat
Adipose Tissue
Type 2 Diabetes Mellitus
Blood Proteins
Colforsin
Insulin Resistance
Fasting
Fatty Acids
Demography

PubMed: MeSH publication types

  • Journal Article

Cite this

Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management. / Jahansouz, Cyrus; Xu, Hongliang; Kizy, Scott; Thomas, Avis J.; Josephrajan, Ajeetha; Hertzel, Ann M; Foncea, Rocio; Connett, John E; Billington, Charles J; Jensen, Michael; Korner, Judith; Bernlohr, David A; Ikramuddin, Sayeed.

In: Surgery (United States), Vol. 165, No. 3, 01.03.2019, p. 571-578.

Research output: Contribution to journalArticle

Jahansouz, Cyrus ; Xu, Hongliang ; Kizy, Scott ; Thomas, Avis J. ; Josephrajan, Ajeetha ; Hertzel, Ann M ; Foncea, Rocio ; Connett, John E ; Billington, Charles J ; Jensen, Michael ; Korner, Judith ; Bernlohr, David A ; Ikramuddin, Sayeed. / Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management. In: Surgery (United States). 2019 ; Vol. 165, No. 3. pp. 571-578.
@article{360935df401c4561afe93b220c0d3e23,
title = "Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management",
abstract = "Background: Serum concentrations of fatty acid binding protein 4, an adipose tissue fatty acid chaperone, have been correlated with insulin resistance and cardiovascular risk factors. The objective of this study were to assess relationships among Roux-en-Y gastric bypass, intensive lifestyle modification and medical management protocol, fatty acid binding protein 4, and metabolic parameters in obese patients with severe type 2 diabetes mellitus; and to evaluate the relative contribution of abdominal subcutaneous adipose and visceral adipose to the secretion of fatty acid binding protein 4. Methods: Participants were randomly assigned to intensive lifestyle modification and medical management protocol (n = 29) or to intensive lifestyle modification and medical management protocol augmented with Roux-en-Y gastric bypass (n = 34). Relationships among fatty acid binding protein 4 and demographic characteristics, metabolic parameters, and 12-month changes in these values were examined. Visceral and subcutaneous adipose tissue explants from obese nondiabetic patients (n = 5) were obtained and treated with forskolin to evaluate relative secretion of fatty acid binding protein 4 in the different adipose tissue depots. Results: The intensive lifestyle modification and medical management protocol and Roux-en-Y gastric bypass cohorts had similar fasting serum fatty acid binding protein 4 concentrations at baseline. At 1 year, mean serum fatty acid binding protein 4 decreased by 42{\%} in Roux-en-Y gastric bypass participants (P =.002) but did not change significantly in the intensive lifestyle modification and medical management protocol cohort. Percentage of weight change was not a significant predictor of 12-month fatty acid binding protein 4 within treatment arm or in multivariate models adjusted for treatment arm. In adipose tissue explants, fatty acid binding protein 4 was secreted similarly between visceral and subcutaneous adipose tissue. Conclusion: After Roux-en-Y gastric bypass, fatty acid binding protein 4 is reduced 12 months after surgery but not after intensive lifestyle modification and medical management protocol in patients with type 2 diabetes mellitus. Fatty acid binding protein 4 was secreted similarly between subcutaneous and visceral adipose tissue explants.",
author = "Cyrus Jahansouz and Hongliang Xu and Scott Kizy and Thomas, {Avis J.} and Ajeetha Josephrajan and Hertzel, {Ann M} and Rocio Foncea and Connett, {John E} and Billington, {Charles J} and Michael Jensen and Judith Korner and Bernlohr, {David A} and Sayeed Ikramuddin",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.surg.2018.08.007",
language = "English (US)",
volume = "165",
pages = "571--578",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management

AU - Jahansouz, Cyrus

AU - Xu, Hongliang

AU - Kizy, Scott

AU - Thomas, Avis J.

AU - Josephrajan, Ajeetha

AU - Hertzel, Ann M

AU - Foncea, Rocio

AU - Connett, John E

AU - Billington, Charles J

AU - Jensen, Michael

AU - Korner, Judith

AU - Bernlohr, David A

AU - Ikramuddin, Sayeed

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: Serum concentrations of fatty acid binding protein 4, an adipose tissue fatty acid chaperone, have been correlated with insulin resistance and cardiovascular risk factors. The objective of this study were to assess relationships among Roux-en-Y gastric bypass, intensive lifestyle modification and medical management protocol, fatty acid binding protein 4, and metabolic parameters in obese patients with severe type 2 diabetes mellitus; and to evaluate the relative contribution of abdominal subcutaneous adipose and visceral adipose to the secretion of fatty acid binding protein 4. Methods: Participants were randomly assigned to intensive lifestyle modification and medical management protocol (n = 29) or to intensive lifestyle modification and medical management protocol augmented with Roux-en-Y gastric bypass (n = 34). Relationships among fatty acid binding protein 4 and demographic characteristics, metabolic parameters, and 12-month changes in these values were examined. Visceral and subcutaneous adipose tissue explants from obese nondiabetic patients (n = 5) were obtained and treated with forskolin to evaluate relative secretion of fatty acid binding protein 4 in the different adipose tissue depots. Results: The intensive lifestyle modification and medical management protocol and Roux-en-Y gastric bypass cohorts had similar fasting serum fatty acid binding protein 4 concentrations at baseline. At 1 year, mean serum fatty acid binding protein 4 decreased by 42% in Roux-en-Y gastric bypass participants (P =.002) but did not change significantly in the intensive lifestyle modification and medical management protocol cohort. Percentage of weight change was not a significant predictor of 12-month fatty acid binding protein 4 within treatment arm or in multivariate models adjusted for treatment arm. In adipose tissue explants, fatty acid binding protein 4 was secreted similarly between visceral and subcutaneous adipose tissue. Conclusion: After Roux-en-Y gastric bypass, fatty acid binding protein 4 is reduced 12 months after surgery but not after intensive lifestyle modification and medical management protocol in patients with type 2 diabetes mellitus. Fatty acid binding protein 4 was secreted similarly between subcutaneous and visceral adipose tissue explants.

AB - Background: Serum concentrations of fatty acid binding protein 4, an adipose tissue fatty acid chaperone, have been correlated with insulin resistance and cardiovascular risk factors. The objective of this study were to assess relationships among Roux-en-Y gastric bypass, intensive lifestyle modification and medical management protocol, fatty acid binding protein 4, and metabolic parameters in obese patients with severe type 2 diabetes mellitus; and to evaluate the relative contribution of abdominal subcutaneous adipose and visceral adipose to the secretion of fatty acid binding protein 4. Methods: Participants were randomly assigned to intensive lifestyle modification and medical management protocol (n = 29) or to intensive lifestyle modification and medical management protocol augmented with Roux-en-Y gastric bypass (n = 34). Relationships among fatty acid binding protein 4 and demographic characteristics, metabolic parameters, and 12-month changes in these values were examined. Visceral and subcutaneous adipose tissue explants from obese nondiabetic patients (n = 5) were obtained and treated with forskolin to evaluate relative secretion of fatty acid binding protein 4 in the different adipose tissue depots. Results: The intensive lifestyle modification and medical management protocol and Roux-en-Y gastric bypass cohorts had similar fasting serum fatty acid binding protein 4 concentrations at baseline. At 1 year, mean serum fatty acid binding protein 4 decreased by 42% in Roux-en-Y gastric bypass participants (P =.002) but did not change significantly in the intensive lifestyle modification and medical management protocol cohort. Percentage of weight change was not a significant predictor of 12-month fatty acid binding protein 4 within treatment arm or in multivariate models adjusted for treatment arm. In adipose tissue explants, fatty acid binding protein 4 was secreted similarly between visceral and subcutaneous adipose tissue. Conclusion: After Roux-en-Y gastric bypass, fatty acid binding protein 4 is reduced 12 months after surgery but not after intensive lifestyle modification and medical management protocol in patients with type 2 diabetes mellitus. Fatty acid binding protein 4 was secreted similarly between subcutaneous and visceral adipose tissue explants.

UR - http://www.scopus.com/inward/record.url?scp=85054149221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054149221&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2018.08.007

DO - 10.1016/j.surg.2018.08.007

M3 - Article

C2 - 30287050

AN - SCOPUS:85054149221

VL - 165

SP - 571

EP - 578

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 3

ER -